The Improvement of the Dissolution Rate of Ziprasidone Free Base from Solid Oral Formulations.
Abstract This work aims at increasing solubility and dissolution rate of ziprasidone free base-Biopharmaceutics Classifaction System (BCS) class II compound. The authors describe a practical approach to amorphization and highlight problems that may occur during the development of formulations containing amorphous ziprasidone, which was obtained by grinding in high-energy planetary ball mills or cryogenic mills. The release of ziprasidone free base from the developed formulations was compared to the reference drug product containing crystalline ziprasidone hydrochloride-Zeldox® hard gelatin capsules. All prepar...
Source: AAPS PharmSciTech - January 16, 2015 Category: Drugs & Pharmacology Authors: Zakowiecki D, Cal K, Kaminski K, Adrjanowicz K, Swinder L, Kaminska E, Garbacz G Tags: AAPS PharmSciTech Source Type: research

Tardive Dyskinesia and Tardive Dystonia With Second-Generation Antipsychotics in Non-Elderly Schizophrenic Patients Unexposed to First-Generation Antipsychotics: A Cross-Sectional and Retrospective Study
This study investigates the clinical nature, prevalence rates, and associated factors of second-generation antipsychotic (SGA)–related tardive dyskinesia and tardive dystonia. To date, these subjects have not been thoroughly investigated.The subjects were 80 non-elderly schizophrenic patients who received SGAs for more than 1 year without any previous exposure to first-generation antipsychotics. Multiple (≥2) direct assessments of movement symptoms were performed. Hospital records longer than 1 recent year describing any observed tardive movement symptoms were reviewed.A current or history of tardive dyskinesia an...
Source: Journal of Clinical Psychopharmacology - December 30, 2014 Category: Psychiatry Tags: Original Contributions Source Type: research

QT Interval Prolongation Associated with Intramuscular Ziprasidone in Chinese Patients: A Case Report and a Comprehensive Literature Review with Meta-Analysis.
Authors: Li XB, Tang YL, Zheng W, Wang CY, de Leon J Abstract Intramuscular (IM) ziprasidone has been associated with QTc interval prolongations in patients with preexisting risk factors. A 23-year-old male Chinese schizophrenia patient experienced an increase of QTc interval of 83 milliseconds (ms) after receiving 20 mg IM ziprasidone (baseline and increased QT/QTc were, respectively, 384/418 and 450/501). This was rated as a probable adverse drug reaction (ADR) by the Liverpool ADR causality assessment tool. A systematic review including all types of trials reporting the effect of IM ziprasidone on the QTc...
Source: Case Reports in Psychiatry - December 29, 2014 Category: Psychiatry Tags: Case Rep Psychiatry Source Type: research

The effectiveness of cross-tapering switching to ziprasidone in patients with schizophrenia or schizoaffective disorder.
CONCLUSION: Cross-tapering switching to ziprasidone is effective for patients with schizophrenia spectrum disorders. Beyond the efficacy of the procedure, favorable metabolic profiles show that switching to ziprasidone may be helpful for maintenance therapy over an extended period. PMID: 25395978 [PubMed] (Source: Psychiatry Investigation)
Source: Psychiatry Investigation - December 2, 2014 Category: Psychiatry Tags: Psychiatry Investig Source Type: research

A case report of priapism caused by ziprasidon.
Authors: Karamustafalioglu N, Kalelioglu T, Tanriover O, Gungor FC, Genc A, Ilnem C Abstract Priapism is defined as having prolonged (more than 6 h), and usually painful penile erection that occurs without a sexual desire or arousal. Only a very few priapism cases caused by ziprasidone are reported in the literature. In this case report we aimed to present a prolonged penile erection due to use of ziprasidone. PMID: 24474994 [PubMed] (Source: Psychiatry Investigation)
Source: Psychiatry Investigation - December 2, 2014 Category: Psychiatry Tags: Psychiatry Investig Source Type: research

Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data
Conclusion The threshold for hyperprolactinemia in D2 occupancy may lie somewhat on a lower side of the established therapeutic window with antipsychotics (i.e. 65–80%). This finding highlights the need for the use of the lowest possible dose to avoid this hormonal side effect in the treatment of schizophrenia. (Source: Progress in Neuro Psychopharmacology and Biological Psychiatry)
Source: Progress in Neuro Psychopharmacology and Biological Psychiatry - November 21, 2014 Category: Psychiatry Source Type: research

Effects of antipsychotics with different weight gain liabilities on human in vitro models of adipose tissue differentiation and metabolism
Publication date: 1 December 2011 Source:Progress in Neuro-Psychopharmacology and Biological Psychiatry, Volume 35, Issue 8 Author(s): Andréa L. Sertié , Angela May Suzuki , Rogério A.L. Sertié , Sandra Andreotti , Fábio B. Lima , Maria Rita Passos-Bueno , Wagner F. Gattaz Weight gain and metabolic abnormalities are serious side effects associated with the use of several second generation antipsychotics (SGA). The adipose tissue has been considered a direct SGA target involved in the development of these adverse effects. Recent studies, mainly using murine cells, have suggested that SGA...
Source: Progress in Neuro Psychopharmacology and Biological Psychiatry - November 21, 2014 Category: Psychiatry Source Type: research

A Bibliometric Study on Second-generation Antipsychotic Drugs in the Asia–Pacific Region
Publication date: August 2014 Source:Journal of Experimental & Clinical Medicine, Volume 6, Issue 4 Author(s): Francisco López-Muñoz , Winston W. Shen , Naotaka Shinfuku , Chi-Un Pae , David J. Castle , Albert K. Chung , Kang Sim , Cecilio Álamo In this review, we analyzed the status and changes in the research on second-generation (atypical) antipsychotic drugs in the Asia–Pacific region (i.e., Japan, South Korea, Taiwan, Hong Kong, Singapore, and Australia). We also performed a bibliometric study of the literature in this region on atypical antipsychotic drugs (e.g., clozapine, risper...
Source: Journal of Experimental and Clinical Medicine - November 3, 2014 Category: Journals (General) Source Type: research

Comparison of Medical Costs and Utilization Associated With Use of Ziprasidone and Olanzapine Among Schizophrenia and Bipolar Disorder Patients
Ziprasidone is increasingly used for the treatment of schizophrenia and bipolar disorder. The purpose of this study is to compare health care costs and utilization associated with use of ziprasidone and olanzapine. (Source: Value in Health)
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: Y. Jiang, J.J. McGinnis, W. Ni Source Type: research

New Drugs of Abuse
Drug abuse is a common problem and growing concern in the United States, and over the past decade, novel or atypical drugs have emerged and have become increasingly popular. Recognition and treatment of new drugs of abuse pose many challenges for health care providers due to lack of quantitative reporting and routine surveillance, and the difficulty of detection in routine blood and urine analyses. Furthermore, street manufacturers are able to rapidly adapt and develop new synthetic isolates of older drugs as soon as law enforcement agencies render them illegal. In this article, we describe the clinical and adverse effects...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - November 1, 2014 Category: Drugs & Pharmacology Authors: Megan A. Rech, Elisabeth Donahey, Jacqueline M. Cappiello Dziedzic, Laura Oh, Elizabeth Greenhalgh Tags: Review of Therapeutics Source Type: research

Ziprasidone monotherapy is ineffective for bipolar-associated anxiety
What is already known on this topic? Anxiety disorders are common among patients with bipolar disorder. Bipolar patients with anxiety disorders have poorer treatment outcomes, greater numbers of suicide attempts, higher rates of substance abuse and lower quality of life.1 Complicating treatment, standard antianxiety agents, such as antidepressants, may worsen the course of bipolar disorder, and there is conflicting evidence about antipsychotics. Some data support the use of quetiapine2 or olanzapine for the treatment of bipolar anxiety, while one trial found risperidone to be ineffective.3 What does this paper add? Ziprasi...
Source: Evidence-Based Mental Health - October 17, 2014 Category: Psychiatry & Psychology Authors: Dunlop, B. W. Tags: Neurology, Substance dependence, Drugs: psychiatry, Bipolar disorder, Suicide (psychiatry), Competing interests (ethics) Pharmacological interventions Source Type: research

Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial
The aim of this study was to evaluate efficacy of ziprasidone monotherapy for major depressive disorder (MDD) with and without psychomotor symptoms. In accordance with the sequential parallel comparison design, 106 MDD patients (age 44.0±10.7 years; female, 43.4%) were recruited and a post-hoc analysis was carried out on 12-week double-blind treatment with either ziprasidone (40–160 mg/day) or placebo, divided into two phases of 6 weeks each to the assigned treatment sequences, drug/drug, placebo/placebo, and placebo/drug. Psychomotor symptoms were evaluated on the basis of the Mini-International Neuropsychiat...
Source: International Clinical Psychopharmacology - October 4, 2014 Category: Psychiatry Tags: Original Articles Source Type: research

Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple‐treatments meta‐analysis
ConclusionOlanzapine + fluoxetine should be first‐line treatment. Olanzapine, quetiapine, lurasidone, valproate and selective serotonin re‐uptake inhibitors are also recommended. Tricyclic antidepressants and lithium are worthy of consideration but lamotrigine (high risk of switching, less robust efficacy) and MAOIs, ziprasidone, aripiprazole and risperidone (no evidence of efficacy) should not be used. (Source: Acta Psychiatrica Scandinavica)
Source: Acta Psychiatrica Scandinavica - October 1, 2014 Category: Psychiatry Authors: D. M. Taylor, V. Cornelius, L. Smith, A. H. Young Tags: Meta‐analysis Source Type: research

Evaluation of the Potential for a Pharmacokinetic Drug–Drug Interaction Between Armodafinil and Ziprasidone in Healthy Adults
Conclusion Systemic exposure to ziprasidone was not affected by pretreatment with armodafinil. Both drugs were generally safe and well tolerated under the conditions studied. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 25, 2014 Category: Drugs & Pharmacology Source Type: research

The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Algorithm for Acute Mania
Abstract: This new algorithm for the pharmacotherapy of acute mania was developed by the Psychopharmacology Algorithm Project at the Harvard South Shore Program. The authors conducted a literature search in PubMed and reviewed key studies, other algorithms and guidelines, and their references. Treatments were prioritized considering three main considerations: (1) effectiveness in treating the current episode, (2) preventing potential relapses to depression, and (3) minimizing side effects over the short and long term. The algorithm presupposes that clinicians have made an accurate diagnosis, decided how to manage contribut...
Source: Harvard Review of Psychiatry - September 1, 2014 Category: Psychiatry Tags: Perspectives Source Type: research

Management of Psychosis and Agitation in Medical-Surgical Patients Who Have or Are at Risk for Prolonged QT Interval
We review the literature on management of psychosis and agitation in medical-surgical patients who have or are at risk for prolonged QT interval, a risk factor for torsade de pointes (TdP), and we describe our protocols for treating these patients. We searched PubMed and PsycInfo for relevant studies and found few papers describing options for treating psychosis and agitation in these patients. Prolonged QTc interval has been more often associated with low-potency phenothiazines such as thioridazine; however, it may occur with high potency typical antipsychotics such as fluphenazine and haloperidol as well as with atypical...
Source: Journal of Psychiatric Practice - September 1, 2014 Category: Psychiatry Tags: Articles Source Type: research

Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs
Abstract This cross-sectional study compared the effects of treatment with atypical antipsychotic drugs on quality of life (QoL) and side effects in 218 patients with schizophrenia attending the ambulatory services of psychiatric in Rio Grande do Norte, Brazil. Socio-economic variables were compared. The five-dimension EuroQoL (EQ-5D) was used to evaluate QoL, and side effects were assessed using the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale and the Simpson–Angus Scale. Data were analysed using the χ 2 test and Student’s t test, with a significance level of...
Source: Psychiatric Quarterly - September 1, 2014 Category: Psychiatry Source Type: research

QTc Interval Prolongation and Torsade de Pointes Associated with Second-Generation Antipsychotics and Antidepressants: A Comprehensive Review
Abstract We comprehensively reviewed published literature to determine whether it supported the link between corrected QT (QTc) interval prolongation and torsade de pointes (TdP) for the 11 second-generation antipsychotics and seven second-generation antidepressants commonly implicated in these complications. Using PubMed and EMBASE, we identified four thorough QT studies (one each for iloperidone, ziprasidone, citalopram, and escitalopram), 40 studies specifically designed to assess QTc interval prolongation or TdP, 58 publications based on data from efficacy and safety trials, 18 toxicology studies, and 102 case...
Source: CNS Drugs - August 29, 2014 Category: Neurology Source Type: research

Characterization and evaluation of self-nanoemulsifying sustained-release pellet formulation of ziprasidone with enhanced bioavailability and no food effect
Drug Delivery, Ahead of Print. (Source: Drug Delivery)
Source: Drug Delivery - August 22, 2014 Category: Drugs & Pharmacology Tags: article Source Type: research

Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12weeks of treatment in first treated episode of psychosis
This randomized open-label study compared the incidence of metabolic side effects of aripiprazole, ziprasidone and quetiapine in a population of medication-naïve first-episode psychosis patients.A total of 202 subjects were enrolled. Body weight, body mass index, leptin, fasting lipids and fasting glycaemic parameters were measured at baseline and at 3months follow-up. A hundred and sixty-six patients completed the follow-up and were included in the analyses. A high proportion of patients experienced a significant weight increase (>7% of their baseline weight): 23% ziprasidone (n=12), 32% with quetiapine (n=16) and...
Source: Schizophrenia Research - August 21, 2014 Category: Psychiatry Authors: Rocio Pérez-Iglesias, Victor Ortiz-Garcia de la Foz, Obdulia Martínez García, Jose Antonio Amado, M. Teresa Garcia-Unzueta, Rosa Ayesa-Arriola, Paula Suarez-Pinilla, Rafael Tabares-Seisdedos, Benedicto Crespo-Facorro Source Type: research

Controlled release of ziprasidone solid dispersion systems from osmotic pump tablets with enhanced bioavailability in the fasted state
Drug Development and Industrial Pharmacy, Ahead of Print. (Source: Drug Development and Industrial Pharmacy)
Source: Drug Development and Industrial Pharmacy - August 20, 2014 Category: Drugs & Pharmacology Tags: article Source Type: research

Novel tricyclic[2,1‐f]theophylline derivatives of LCAP with activity in mouse models of affective disorders
ConclusionsThe present preclinical results indicate that one of the two investigated imidazo[2,1‐f]purine‐2,4‐dione derivatives, compound 9, with methyl group at 7 position of imidazo[2,1‐f]purine‐2,4‐dione fragment and the ortho‐OCH3 substituent in the aryl moiety, acts as an antipsychotic drug with additional antidepressant and anxiolytic properties. (Source: Journal of Pharmacy and Pharmacology)
Source: Journal of Pharmacy and Pharmacology - August 13, 2014 Category: Drugs & Pharmacology Authors: Anna Partyka, Jakub Jarosz, Anna Wasik, Magdalena Jastrzębska‐Więsek, Agnieszka Zagórska, Maciej Pawłowski, Anna Wesołowska Tags: Research Paper Source Type: research

Open prospective study of ziprasidone in patients with schizophrenia with depressive symptoms: A multicenter study
AimsThe goal of this study was to examine the efficacy and safety of ziprasidone to treat depressive symptoms in Korean patients with schizophrenia who showed stable symptoms. MethodsIn this 8‐week, open‐label, prospective, non‐randomized, multicenter study, 34 patients with schizophrenia who showed a stable response to previous medications, maintained a stable dose, and who had depressive symptoms, were recruited. Ziprasidone was the only antipsychotic agent allowed for 8 weeks after a 2–7‐week washout period. ResultsSteady decreases were observed on the Montgomery–Asberg Depression Rating Scale, the C...
Source: Psychiatry and Clinical Neurosciences - July 29, 2014 Category: Neuroscience Authors: Woo‐Young Jung, Sung‐Gon Kim, Jin‐Seong Lee, Dong‐Ho Kang, Bong‐Joo Jung, Dong‐Hun Shin, Young‐Min Lee, Sang‐Heon Choi Tags: Regular Article Source Type: research

Extrapyramidal symptoms during treatment of first schizophrenia episode: Results from EUFEST
The European First Episode Schizophrenia Trial (EUFEST) included first-episode schizophrenia patients, assessing the efficacy of five antipsychotic drugs (haloperidol, amisulpride, olanzapine, quetiapine and ziprasidone) over one year. Baseline frequency of extrapyramidal symptoms (EPS) in this group of patients (n=490) was as follows: parkinsonism 10.8%, akathisia 10.0%, dystonia 1.8%, and dyskinesia 0.6%. The frequency of parkinsonism at baseline was greater in patients with a brief prior exposure to antipsychotics (≤2 weeks) compared with antipsychotic-naïve ones, and was positively correlated with the intensity...
Source: European Neuropsychopharmacology - July 21, 2014 Category: Psychiatry & Psychology Authors: Janusz K. Rybakowski, Kristof Vansteelandt, Agnieszka Remlinger-Molenda, W. Wolfgang Fleischhacker, René S. Kahn, Joseph Peuskens, for the EUFEST Study Group Source Type: research

Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in vitro.
In this study, we investigated changes in the expression levels of critical regulatory genes of adipogenesis, lipid metabolism and proinflammatory genes during the differentiation of primary human adipose-derived stem cells (ADSCs). These cells were isolated from patients with body mass indices
Source: Biochemical and Biophysical Research communications - July 11, 2014 Category: Biochemistry Authors: Sárvári AK, Veréb Z, Uray IP, Fésüs L, Balajthy Z Tags: Biochem Biophys Res Commun Source Type: research

Treatment with Ziprasidone for schizophrenia patients with OCD
Comorbidity of obsessive–compulsive disorder (OCD) has been observed in about 15% of schizophrenic patients and has been associated with poor prognosis. Therefore, there is a need for specific treatment options for these patients (schizo-obsessive, ScOCD).This is an open, prospective study, aiming to test the efficacy of Ziprasidone (80–200mg/d) in ScOCD patients and comparing the response to the treatment between stable schizophrenic (N=16) and stable ScOCD (N=29) patients.Treatment effect with Ziprasidone was different in schizophrenic patients when stratified based on OCD comorbidity. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - July 3, 2014 Category: Psychiatry & Psychology Authors: Alzbeta Juven-Wetzler, Leah Fostick, Shlomit Cwikel-Hamzany, Evgenya Balaban, Joseph Zohar Source Type: research

Comparative mortality risks of antipsychotic medications in community-dwelling older adults [PAPERS]
Conclusions Significant variation in mortality risk across commonly prescribed antipsychotics suggests that antipsychotic selection and dosing may affect survival of older people living in the community. (Source: The British Journal of Psychiatry)
Source: The British Journal of Psychiatry - July 1, 2014 Category: Psychiatry Authors: Gerhard, T., Huybrechts, K., Olfson, M., Schneeweiss, S., Bobo, W. V., Doraiswamy, P. M., Devanand, D. P., Lucas, J. A., Huang, C., Malka, E. S., Levin, R., Crystal, S. Tags: PAPERS Source Type: research

Practitioner Review: Long‐term pharmacological treatment of pediatric bipolar disorder
ConclusionAccording to the limited empirical evidence, aripiprazole can be useful for relapse prevention in children with PBD. Given the lack of consistent efficacy data, clinical decision making should be based on individual clinical aspects and safety concerns. (Source: Journal of Child Psychology and Psychiatry)
Source: Journal of Child Psychology and Psychiatry - June 6, 2014 Category: Psychiatry Authors: Covadonga M. Díaz‐Caneja, Carmen Moreno, Cloe Llorente, Ana Espliego, Celso Arango, Dolores Moreno Tags: Practitioner Review Source Type: research

An Open Prospective Study of Ziprasidone in Patients with Schizophrenia with Depressive Symptoms: A Multi‐Center Study
Abstract AimsThe goal of this study was to examine the efficacy and safety of ziprasidone to treat depressive symptoms in Korean patients with schizophrenia who showed stable symptoms. MethodsIn this 8‐week, open label, prospective, nonrandomized, multi‐center study, 34 patients with schizophrenia who showed a stable response to previous medications, maintained a stable dose, and who had depressive symptoms were recruited. Ziprasidone was the only antipsychotic agent allowed for 8 weeks after a 2–7 week washout period. ResultsSteady decreases were observed on the Montgomery–Asberg Depression Rating Scale (M...
Source: Psychiatry and Clinical Neurosciences - June 6, 2014 Category: Neuroscience Authors: Woo‐Young Jung, Sung‐Gon Kim, Jin‐Seong Lee, Dong‐Ho Kang, Bong‐Joo Jung, Dong‐Hun Shin, Young‐Min Lee, Sang‐Heon Choi Tags: Regular Article Source Type: research

Prevalence of Pre-existing Risk Factors for Adverse Events Associated with Atypical Antipsychotics among Commercially Insured and Medicaid Insured Patients Newly Initiating Atypical Antipsychotics.
Conclusions: Despite the availability of several AAs to treat psychiatric conditions, pre-existing AE risk factors can limit patient treatment options. Given inter-AA variability in risk factors, open access to AA may help to optimize appropriate prescribing. PMID: 24909573 [PubMed - as supplied by publisher] (Source: Current Drug Safety)
Source: Current Drug Safety - June 1, 2014 Category: Drugs & Pharmacology Authors: Citrome L, Johnston S, Nadkarni A, Sheehan JJ, Kamat SA, Kalsekar I Tags: Curr Drug Saf Source Type: research

Pharmacogenetics of adverse events in schizophrenia treatment: Comparison study of ziprasidone, olanzapine and perazine
(Source: Psychiatry Research)
Source: Psychiatry Research - May 29, 2014 Category: Psychiatry Authors: Piotr Tybura, Beata Trześniowska-Drukała, Przemyslaw Bienkowski, Aleksander Beszlej, Dorota Frydecka, Pawel Mierzejewski, Agnieszka Samochowiec, Anna Grzywacz, Jerzy Samochowiec Source Type: research

Clinical decision making in the treatment of mixed states.
Conclusions. There is a lack of studies designed to address the efficacy of medications in mixed affective symptoms. Guidelines do not fully reflect the current evidences. PMID: 24824425 [PubMed - as supplied by publisher] (Source: The World Journal of Biological Psychiatry)
Source: The World Journal of Biological Psychiatry - May 14, 2014 Category: Psychiatry Authors: Grunze H, Azorin JM Tags: World J Biol Psychiatry Source Type: research

Optimal Sampling of Antipsychotic Medicines: A Pharmacometric Approach for Clinical Practice
ConclusionThis analysis provides important sampling information for future population pharmacokinetic studies and clinical studies investigating the pharmacokinetics of antipsychotic medicines. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - April 29, 2014 Category: Drugs & Pharmacology Authors: Vidya Perera, Robert R Bies, Gary Mo, Michael J Dolton, Vaughan J Carr, Andrew J McLachlan, Richard O Day, Thomas M Polasek, Alan Forrest Tags: Pharmacokinetics Source Type: research

Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: Findings from the NIMH CATIE study
This study examined the effects of antipsychotic medication on overall life satisfaction in patients with chronic schizophrenia. Data were drawn from the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) study, where participants with a DSM-IV diagnosis of schizophrenia were randomized to receive olanzapine, perphenazine, quetiapine, risperidone or ziprasidone under double-blind conditions (N=753). The primary outcome measure was prospective change in subjectively evaluated overall life satisfaction scores following 12 months of antipsychotic treatment. Psychopathology, medication side effects and function...
Source: European Neuropsychopharmacology - April 14, 2014 Category: Psychiatry & Psychology Authors: Gagan Fervaha, Ofer Agid, Hiroyoshi Takeuchi, George Foussias, Gary Remington Tags: Clinical Science Source Type: research

Atypical Antipsychotic Utilization in Dementia Patients at a Long-Term Care Facility: A Retrospective Study (P3.206)
CONCLUSIONS: Atypical antipsychotics used in low doses for psychotic related behaviors were highly effective and well tolerated in this population. Despite black-box warnings, antipsychotics should not be discouraged in this setting. Further prospective study is urged.Disclosure: Dr. Scharre has received personal compensation for activities with Forest Laboratories Inc. for speaking, and with Eli Lilly & Co. as a consultant. Dr. Scharre has received research support from Pfizer Inc., Janssen Alzheimer Immunotherapy, Bristol Myers Squibb Co., Phylogeny, and the Mangurian Foundation. Dr. Chang has received research suppo...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Scharre, D., Chang, S.-I., Nagaraja, H., Merjanian, M., Greenley, G., Davis, R. Tags: Aging, Dementia, and Cognitive and Behavioral Neurology: Clinical Aspects Source Type: research

Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: A randomized study.
CONCLUSIONS: Results from this small pilot RCT suggest beneficial effects of both clozapine and ziprasidone in the treatment of cannabis use disorders in psychotic patients. Larger-scale RCTs are needed in order to assess advantages and disadvantages of the different SGAs in dually diagnosed populations. (Am J Addict 2014;9999:1-5). PMID: 24628830 [PubMed - as supplied by publisher] (Source: American Journal on Addictions)
Source: American Journal on Addictions - March 15, 2014 Category: Addiction Authors: Schnell T, Koethe D, Krasnianski A, Gairing S, Schnell K, Daumann J, Gouzoulis-Mayfrank E Tags: Am J Addict Source Type: research

Evidence Base for Using Atypical Antipsychotics for Psychosis in Adolescents
Atypical antipsychotic medications have been the first line of treatment for adolescents with psychosis in the past couple of decades. Till the late 90s, there were very few randomized controlled trials (RCTs) on the treatment of adolescents with psychosis, although a fifth of schizophrenia starts during adolescence. Most of the treatment guidelines for adolescents with psychosis were derived from data on adults. In the past 10 years, there has been increasing number of studies on adolescents with psychosis. The current paper summarizes the findings of trials on adolescents with psychosis in 4 groups: (a) atypical antipsyc...
Source: Schizophrenia Bulletin - February 22, 2014 Category: Psychiatry Authors: Datta, S. S., Kumar, A., Wright, S. D., Furtado, V. A., Russell, P. S. Tags: Cochrane Corner Source Type: research

Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method
Conclusions: This method for determining antipsychotic dose equivalence entails an operationalized and evidence-based approach that can be applied to the various antipsychotic drugs. As a limitation, the results are not applicable to specific populations such as first-episode or refractory patients. We recommend that alternative methods also be updated in order to minimize further differences between the methods and risk of subsequent bias. (Source: Schizophrenia Bulletin)
Source: Schizophrenia Bulletin - February 22, 2014 Category: Psychiatry Authors: Leucht, S., Samara, M., Heres, S., Patel, M. X., Woods, S. W., Davis, J. M. Tags: Regular Article Source Type: research

Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data
The objective of this study was to evaluate the relationship between antipsychotic-induced tardive dyskinesia (TD) and estimated dopamine D2 receptor occupancy levels in patients with schizophrenia, using the dataset from the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE).Methods: The dataset from 218 subjects (risperidone, N=78; olanzapine, N=100; ziprasidone, N=40) who presented with a score of zero on the Abnormal Involuntary Movement Scale (AIMS) at baseline in Phase 1 of the CATIE study, and remained for ≥6months, was used. Peak and trough dopamine D2 receptor occupancy levels on the day of the...
Source: Schizophrenia Research - February 3, 2014 Category: Psychiatry Authors: Kazunari Yoshida, Robert R. Bies, Takefumi Suzuki, Gary Remington, Bruce G. Pollock, Yuya Mizuno, Masaru Mimura, Hiroyuki Uchida Tags: Neuropharmacology Source Type: research

Effects Of Acute And Long-Term Typical Or Atypical Neuroleptics On Morphine-Induced Behavioural Effects In Mice.
This article is protected by copyright. All rights reserved. PMID: 24471703 [PubMed - as supplied by publisher] (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - January 28, 2014 Category: Drugs & Pharmacology Authors: Hollais AW, Patti CL, Zanin KA, Fukushiro DF, Berro LF, Carvalho RC, Kameda SR, Frussa-Filho R Tags: Clin Exp Pharmacol Physiol Source Type: research

Perazine for schizophrenia.
CONCLUSIONS: The number, size and reporting of randomised controlled perazine trials are insufficient to present firm conclusions about the properties of this antipsychotic. It is possible that perazine is associated with a similar risk of extrapyramidal side-effects as some atypical antipsychotics but this is based on small comparisons. This should be clarified in larger, well-designed trials. PMID: 24425538 [PubMed - as supplied by publisher] (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - January 15, 2014 Category: Journals (General) Authors: Leucht S, Helfer B, Hartung B Tags: Cochrane Database Syst Rev Source Type: research

Aripiprazole versus other atypical antipsychotics for schizophrenia.
CONCLUSIONS: Information on all comparisons is of limited quality, is incomplete and problematic to apply clinically. The quality of the evidence is all low or very low. Aripiprazole is an antipsychotic drug with an important adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerge from ongoing larger, independent pragmatic trials. PMID: 24385408 [PubMed - as supplied by publisher] (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - January 2, 2014 Category: Journals (General) Authors: Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, Leucht S, Xia J Tags: Cochrane Database Syst Rev Source Type: research

A bibliometric study of scientific research conducted on second-generation antipsychotic drugs in Singapore.
CONCLUSION: Publications on SGAs in Singapore are still too few to confirm an exponential growth of scientific literature. PMID: 24452974 [PubMed - in process] (Source: Singapore Medical Journal)
Source: Singapore Medical Journal - January 1, 2014 Category: Journals (General) Authors: López-Muñoz F, Sim K, Shen WW, Huelves L, Moreno R, Molina JD, Rubio G, Noriega C, Pérez-Nieto MA, Alamo C Tags: Singapore Med J Source Type: research

Table of Contents
Abstract CDC study finds increases in diagnosis and slower increases for treatment for ADHD Illicit methadone and buprenorphine use minimal in Sweden Poverty linked to reduced brain development Mental health visits for children and adolescents increasing, decreasing for adults Antipsychotic‐naïve patients more likely to experience side effects of aripiprazole Ziprasidone found ineffective compared to placebo in trial with adolescents Failed specifications (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - December 20, 2013 Category: Psychiatry Source Type: research

[Correspondence] Efficacy of antipsychotic drugs for schizophrenia
We read with great interest Stefan Leucht and colleagues' meta-analysis (Sept 14, p 951). It is remarkable that the five newest antipsychotics—ziprasidone, aripiprazole, asenapine, iloperidone, and lurasidone—are at the bottom of the efficacy and all-cause discontinuation figures, although there are no known pharmacological differences to explain these findings. Here, we suggest that they form a subclass of antipsychotics with administration issues that lower total drug exposure. We believe that pharmacokinetics can explain the differences in efficacy of antipsychotics. (Source: LANCET)
Source: LANCET - December 7, 2013 Category: Journals (General) Authors: Philippe D Vincent, Edouard Kouassi Tags: Correspondence Source Type: research

[Correspondence] Efficacy of antipsychotic drugs for schizophrenia – Authors' reply
Philippe Vincent and Edouard Kouassi make a valid point about the complex pharmacokinetics of some newer antipsychotic drugs. We believe that knowledge of these pharmacokinetics is essential for getting the best results from treatment and that these issues might be under-recognised in clinical practice. For example, even though the majority of the trials included in our meta-analysis were phase 3 studies with strict protocols, it cannot be ruled out that ziprasidone or lurasidone were sometimes taken without sufficient food. (Source: LANCET)
Source: LANCET - December 7, 2013 Category: Journals (General) Authors: Stefan Leucht, Andrea Cipriani, John R Geddes, Georgia Salanti, John M Davis Tags: Correspondence Source Type: research

Clinical and regulatory implications of active run‐in phases in long‐term studies for bipolar disorder
ConclusionExtrapolation of results from enrichment studies to the more general population of patients should be carried out cautiously because average treatment benefits are likely to be less in unselected patients. Clear guidance for regulatory submission of RCTs is needed. (Source: Acta Psychiatrica Scandinavica)
Source: Acta Psychiatrica Scandinavica - December 1, 2013 Category: Psychiatry Authors: A. Cipriani, C. Barbui, J. Rendell, J. R. Geddes Tags: Review Source Type: research

Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
This study aimed to compare the effects of olanzapine, perphenazine, risperidone, quetiapine, and ziprasidone on hostility in schizophrenia. METHODS: We used the data that were acquired in the 18-month Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. We analyzed the scores of the Positive and Negative Syndrome Scale (PANSS) hostility item in a subset of 614 patients who showed at least minimal hostility (a score ≥ 2) at baseline. RESULTS: The primary analysis of hostility indicated an effect of difference between treatments (F4,1487 = 7.78, P
Source: CNS Spectrums - November 28, 2013 Category: Neurology Authors: Volavka J, Czobor P, Citrome L, Van Dorn RA Tags: CNS Spectr Source Type: research

Quetiapine versus other atypical antipsychotics for schizophrenia.
CONCLUSIONS: Available evidence from trials suggests that most people who start quetiapine stop taking it within a few weeks (around 60%). Comparisons with amisulpride, sertindole and zotepine do not exist. Although efficacy data favour olanzapine and risperidone compared with quetiapine, the clinical meaning of these data remains unclear. Quetiapine may produce fewer parkinsonian effects than paliperidone, aripiprazole, ziprasidone, risperidone and olanzapine. Quetiapine appears to have a similar weight gain profile to risperidone, as well as clozapine and aripiprazole (although data are very limited for the latter t...
Source: Cochrane Database of Systematic Reviews - November 18, 2013 Category: Journals (General) Authors: Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S Tags: Cochrane Database Syst Rev Source Type: research

Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone
ConclusionThe study data indicated that carriage of the ADRA2A rs1800544 GG genotype and the MTHFR rs1801131 C allele are associated with BMI reduction in this population following switching of antipsychotics to aripiprazole and ziprasidone. Copyright © 2013 John Wiley & Sons, Ltd. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - November 1, 2013 Category: Psychiatry Authors: Siti Norsyuhada Roffeei, Gavin P. Reynolds, Nor Zuraida Zainal, Mas Ayu Said, Ahmad Hatim, Syarinaz Ahmad Aida, Zahurin Mohamed Tags: Research Article Source Type: research